| ŽÁČKOVÁ, Daniela, H. KLAMOVÁ, Ladislav DUŠEK, Jan MUŽÍK, B DOBESOVA, Jaroslava RYŠAVÁ, Zdeněk RÁČIL, Michael DOUBEK, Dana DVOŘÁKOVÁ, Tomáš JURČEK, Filip RÁZGA, J MORAVCOVA, K POLAKOVA, Jarmila RULCOVÁ, Petr CETKOVSKÝ a Jiří MAYER. Imatinib in the first line chronic myeloid leukemia (CML) treatment. Can we compare the real-life data to clinical trial results? In Haematologica - the hematology journal 95, S2, od s. 350-350. 2010. |
Další formáty:
BibTeX
LaTeX
RIS
@proceedings{921261,
author = {Žáčková, Daniela and Klamová, H. and Dušek, Ladislav and Mužík, Jan and Dobesova, B and Ryšavá, Jaroslava and Ráčil, Zdeněk and Doubek, Michael and Dvořáková, Dana and Jurček, Tomáš and Rázga, Filip and Moravcova, J and Polakova, K and Rulcová, Jarmila and Cetkovský, Petr and Mayer, Jiří},
booktitle = {Haematologica - the hematology journal 95, S2, od s. 350-350},
language = {eng},
title = {Imatinib in the first line chronic myeloid leukemia (CML) treatment. Can we compare the real-life data to clinical trial results?},
year = {2010}
}
TY - CONF
ID - 921261
AU - Žáčková, Daniela - Klamová, H. - Dušek, Ladislav - Mužík, Jan - Dobesova, B - Ryšavá, Jaroslava - Ráčil, Zdeněk - Doubek, Michael - Dvořáková, Dana - Jurček, Tomáš - Rázga, Filip - Moravcova, J - Polakova, K - Rulcová, Jarmila - Cetkovský, Petr - Mayer, Jiří
PY - 2010
TI - Imatinib in the first line chronic myeloid leukemia (CML) treatment. Can we compare the real-life data to clinical trial results?
ER -
ŽÁČKOVÁ, Daniela, H. KLAMOVÁ, Ladislav DUŠEK, Jan MUŽÍK, B DOBESOVA, Jaroslava RYŠAVÁ, Zdeněk RÁČIL, Michael DOUBEK, Dana DVOŘÁKOVÁ, Tomáš JURČEK, Filip RÁZGA, J MORAVCOVA, K POLAKOVA, Jarmila RULCOVÁ, Petr CETKOVSKÝ a Jiří MAYER. Imatinib in the first line chronic myeloid leukemia (CML) treatment. Can we compare the real-life data to clinical trial results? In \textit{Haematologica - the hematology journal 95, S2, od s. 350-350}. 2010.
|
